OccuRx
Primary focus is on the development of innovative therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD51—77m (Dealroom.co estimates Sep 2022.)
Company register number 164284440
Melbourne Victoria (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
AUD6.5m | Late VC | ||
AUD50.0k | Grant | ||
* | AUD14.5m | Late VC | |
* | AUD1.5m | Grant | |
| Total Funding | CAD19.9m | ||
Related Content
Recent News about OccuRx
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.